Se connecter

Bibliographies thématiques / Sarcomatoid subtype / Articles de revues

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Sarcomatoid subtype.

Articles de revues sur le sujet « Sarcomatoid subtype »

Auteur : Grafiati

Publié le 7 juin 2025

Mis à jour le 2 août 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Sarcomatoid subtype ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Santoso, Agus, Ngakan Putra, Ungky Setiawan, Artono Isharanto, Dini Erawati, and Hendy Yudhanto. "Sarcomatoid Carcinoma Of The Mediastinal : A Rare Case of Giant Mass Thymic Carcinoma Subtype." Malang Respiratory Journal 3, no. 1 (2021): 133–38. http://dx.doi.org/10.21776/ub.mrj.2021.003.01.4.

Texte intégral

Résumé :

Introduction: Sarcomatoid carcinoma is a type of thymus carcinoma that contains partial or complete spindle cells. Incidence of Sarcomatoid Carcinoma 5-10% of all patients with thymic carcinoma. Carcinoma Sarcomatoid is a highly progressive tumor, most patients will die after 3 years of diagnosis despite aggressive multimodality therapy. Case Description: A 47-year-old woman with chest pain, shortness of breath, coughing, weight loss, enlarging lump in the neck and chest was felt for 1 month. Physical and supporting examination showed anterior superior mediastinal tumors and soft mass tissue i

Styles APA, Harvard, Vancouver, ISO, etc.

2

Santoso, Agus, Ngakan Putra, Ungky Setiawan, Artono Isharanto, Dini Erawati, and Hendy Yudhanto. "Sarcomatoid Carcinoma Of The Mediastinal : A Rare Case of Giant Mass Thymic Carcinoma Subtype." Malang Respiratory Journal 3, no. 1 (2021): 133–38. http://dx.doi.org/10.21776/ub.mrj.2021.003.01.4.

Texte intégral

Résumé :

Introduction: Sarcomatoid carcinoma is a type of thymus carcinoma that contains partial or complete spindle cells. Incidence of Sarcomatoid Carcinoma 5-10% of all patients with thymic carcinoma. Carcinoma Sarcomatoid is a highly progressive tumor, most patients will die after 3 years of diagnosis despite aggressive multimodality therapy. Case Description: A 47-year-old woman with chest pain, shortness of breath, coughing, weight loss, enlarging lump in the neck and chest was felt for 1 month. Physical and supporting examination showed anterior superior mediastinal tumors and soft mass tissue i

Styles APA, Harvard, Vancouver, ISO, etc.

3

Pecoraro, Angela, Giuseppe Rosiello, Stefano Luzzago, et al. "Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines." Journal of the National Comprehensive Cancer Network 18, no. 10 (2020): 1340–47. http://dx.doi.org/10.6004/jnccn.2020.7577.

Texte intégral

Résumé :

Background: The NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer recommend active surveillance as an option for initial management of T1a 0- to 2-cm renal lesions, in addition to partial nephrectomy, radical nephrectomy, and focal ablation. However, contemporary data regarding the distribution of patient and renal cell carcinoma characteristics within this special patient group are scarce. Methods: Within the SEER database (2002–2016), 13,364 patients with T1aNanyMany 0- to 2-cm renal lesions treated with nephrectomy were identified. Data were tabulated according to histologic s

Styles APA, Harvard, Vancouver, ISO, etc.

4

Park, Hyung Kyu. "The Metastasis Pattern of Renal Cell Carcinoma Is Influenced by Histologic Subtype, Grade, and Sarcomatoid Differentiation." Medicina 59, no. 10 (2023): 1845. http://dx.doi.org/10.3390/medicina59101845.

Texte intégral

Résumé :

Background and Objectives: Metastasis is a major cause of death in renal cell carcinoma (RCC) patients; therefore, a better understanding of the metastatic process and the ability to predict metastasis in advance is important for treating patients with RCC. This study aimed to investigate whether histological subtypes of RCC and other factors, such as nuclear grade and sarcomatoid differentiation, could predict the probability and location of metastases in patients with RCC. Materials and Methods: Cases of clear-cell, papillary, chromophobe, and sarcomatoid RCC were retrieved and analyzed from

Styles APA, Harvard, Vancouver, ISO, etc.

5

Polyakova, A. S., E. A. Sokolov, and D. Yu Pushkar. "Effectiveness of pembrolizumab in therapy of sarcomatoid variant of metastatic urothelial carcinoma. Clinical case." Cancer Urology 20, no. 4 (2025): 104–11. https://doi.org/10.17650/1726-9776-2024-20-4-104-111.

Texte intégral

Résumé :

Sarcomatoid variant of urothelial carcinoma is a rare histological subtype: it is diagnosed in 0.1–0.3 % of all neoplasms of the bladder. The standard 1st line therapy for all types of advanced urothelial carcinoma is chemotherapy which does not necessarily allow to achieve the best or complete responses, especially in the presence of sarcomatoid differentiation. High programmed cell death-ligand 1 (PD-L1) expression in this morphological subtype allows to assume better results of immunotherapy compared to chemotherapy. However, a large number of observations is necessary to confirm this hypot

Styles APA, Harvard, Vancouver, ISO, etc.

6

Rahman, Syed, David Hesse, Michael Jalfon, Victoria Kong, and Fady Ghali. "Evaluating the therapeutic role of lymph node dissection in variant histology bladder cancer." Journal of Clinical Oncology 43, no. 5_suppl (2025): 749. https://doi.org/10.1200/jco.2025.43.5_suppl.749.

Texte intégral

Résumé :

749 Background: Outcome benefit associated with lymph node dissection (LND) at time of radical cystectomy have been suggested in urothelial bladder cancer (BC), but have not been evaluated in variant subtype BC. Our objective was to characterize the impact of LND on survival outcomes across variant subtype BC. Methods: The National Cancer Database was queried for cases of variant histology bladder cancers using International Classification of Disease-O-3 morphologic codes managed with radical cystectomy between 2004 and 2020. Cases were stratified by variant subtype and LND status. Primary out

Styles APA, Harvard, Vancouver, ISO, etc.

7

Di Stefano, Iosè, Greta Alì, Anello Marcello Poma, et al. "New Immunohistochemical Markers for Pleural Mesothelioma Subtyping." Diagnostics 13, no. 18 (2023): 2945. http://dx.doi.org/10.3390/diagnostics13182945.

Texte intégral

Résumé :

Pleural mesothelioma (PM) comprises three main subtypes: epithelioid, biphasic and sarcomatoid, which have different impacts on prognosis and treatment definition. However, PM subtyping can be complex given the inter- and intra-tumour morphological heterogeneity. We aim to use immunohistochemistry (IHC) to evaluate five markers (Mesothelin, Claudin-15, Complement Factor B, Plasminogen Activator Inhibitor 1 and p21-activated Kinase 4), whose encoding genes have been previously reported as deregulated among PM subtypes. Immunohistochemical expressions were determined in a case series of 73 PMs,

Styles APA, Harvard, Vancouver, ISO, etc.

8

Fatima, Syeda, Hafeza Syeda, Naushaba Tazeen, Idrees Afroze, and Mohammed Adil. "Renal cell carcinomas’ hidden challenge: Sarcomatoid differentiation uncovered." Journal of Medical and Allied Sciences 15, no. 1 (2025): 99. https://doi.org/10.5455/jmas.215330.

Texte intégral

Résumé :

Renal cell carcinoma (RCC) with sarcomatoid differentiation accounts for 4% of all RCC cases. This aggressive variant is characterized by spindle-shaped tumor cells and carries a high risk of metastasis and poor outcomes. Accurate diagnosis is crucial due to its aggressiveness and the limited treatment options. A 55-year-old male presented to the nephrology department with right lumbar pain, hematuria, and burning micturition. Radiology showed an enlarged right kidney with a hetero-echoic mass (7x5x2cm) across the mid and lower pole. He underwent right nephrectomy followed by histopathological

Styles APA, Harvard, Vancouver, ISO, etc.

9

Anusim, Nwabundo, Damilola Gbadebo, Olabisi Afolayan-Oloye, and Ishmael Jaiyesimi. "Durable Remission with Immunotherapy in a Patient with Sarcomatoid Renal Cell Carcinoma." Journal of Kidney Cancer and VHL 8, no. 4 (2021): 38–42. http://dx.doi.org/10.15586/jkcvhl.v8i4.168.

Texte intégral

Résumé :

Sarcomatoid differentiation is a rare and aggressive histologic subtype with poor prognosis, seen in several malignancies. In sarcomatoid renal cell carcinoma (RCC), the degree of sarcomatoid differentiation and the stage at presentation determines the prognosis. Despite resection, chemotherapy and targeted therapy response is modest, with relapse usually occurring within a few months. We present a case of a gentleman with sarcomatoid RCC managed with pembrolizumab, who has had no evidence of recurrence for over 4 years since the last dose of immunotherapy. RCCs with sarcomatoid differentiatio

Styles APA, Harvard, Vancouver, ISO, etc.

10

Jeong, Han-Sin, Young-Ik Son, Young-Hyeh Ko, and Sang Yoon Kim. "Sarcomatoid salivary duct carcinoma of the larynx." Journal of Laryngology & Otology 120, no. 2 (2005): 154–57. http://dx.doi.org/10.1017/s0022215105003518.

Texte intégral

Résumé :

The sarcomatoid variant is a rare subtype of salivary duct carcinoma that comprises epithelial and sarcomatoid components. The authors present the first reported case of sarcomatoid salivary duct carcinoma occurring in the larynx, which was successfully treated by partial laryngectomy with ipsilateral neck dissection, with no evidence of recurrence after five years.Microscopic analysis revealed a composite epithelial and sarcomatoid tumour. The epithelial component was characterized by papillary proliferation of glandular and ductal structures lined with multilayered epithelial tumour cells. T

Styles APA, Harvard, Vancouver, ISO, etc.

11

Akhtar, Kafil, Pragati Agnihotri, Kiran Alam, and Kashif Raza. "Unusual Case of Coexisting Renal Malignancies: Mucinous Tubular and Spindle Cell Carcinoma Kidney with Sarcomatoid Change." Journal of Kidney Cancer and VHL 3, no. 2 (2016): 8–13. http://dx.doi.org/10.15586/jkcvhl.2016.51.

Texte intégral

Résumé :

Mucinous tubular and spindle cell carcinoma (MTSCC) is a recent entity introduced in the World Health Organization 2004 Classification. It is a tumour of low malignant potential. MTSCC is a subtype of renal cell carcinoma (RCC), which is characterized by a polymorphous histology, wherein the spindled epithelial cell is an inherent carcinomatous component. We report the case of a 57-year-old man presenting with loin pain and dragging sensation. Imaging revealed a large mass arising from the left kidney. Radical nephrectomy was performed, and histopathology revealed spindle cell elements of MTSC

Styles APA, Harvard, Vancouver, ISO, etc.

12

Aird, John James, Aisling U. Nic an Riogh, Stewart Fleming, R. Gordon Hislop, Paul Sweeney, and Nick Mayer. "Papillary Renal Cell Carcinoma With Osteosarcomatous Heterologous Differentiation: A Case Report With Molecular Genetic Analysis and Review of the Literature." International Journal of Surgical Pathology 25, no. 8 (2017): 745–50. http://dx.doi.org/10.1177/1066896917716772.

Texte intégral

Résumé :

Sarcomatoid differentiation can occur in all subtypes of renal cell carcinoma (RCC). In rare cases, heterologous differentiation has been described. We present a case of heterologous osteosarcomatous differentiation in association with sarcomatoid papillary RCC including an analysis of chromosomal copy number alteration. This is the first case to identify heterologous differentiation in association with papillary RCC. The patient was a 70-year-old man who had a mass in the right kidney. Speckled calcification was seen on computed tomography scan. Histological assessment demonstrated papillary

Styles APA, Harvard, Vancouver, ISO, etc.

13

Quiroga-Garza, Gabriela, Hema Khurana, Steven Shen, Alberto G. Ayala, and Jae Y. Ro. "Sarcomatoid Chromophobe Renal Cell Carcinoma With Heterologous Sarcomatoid Elements." Archives of Pathology & Laboratory Medicine 133, no. 11 (2009): 1857–60. http://dx.doi.org/10.5858/133.11.1857.

Texte intégral

Résumé :

Abstract Chromophobe renal cell carcinoma (CRCC) is a distinct subtype of renal cell carcinoma (RCC) that is well known for its relatively good prognosis. Sarcomatoid transformation in this tumor, although rare, has been well documented in the literature and, as in other types of RCC, carries an ominous prognosis for the patient. The finding of heterologous elements in the sarcomatoid component of CRCC is an extraordinary event, which has been reported in only 2 previous cases. Here, we present the third such case, occurring in the left kidney of a previously healthy 63-year-old woman. The nep

Styles APA, Harvard, Vancouver, ISO, etc.

14

Liu, Bolun, Changchuan Jiang, Kristopher Attwood, Stuthi Perimbeti, Hongbin Chen, and Lei Deng. "Survival outcome of metastatic pulmonary sarcomatoid carcinoma in immunotherapy era: An NCDB analysis." Journal of Clinical Oncology 42, no. 16_suppl (2024): 8555. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8555.

Texte intégral

Résumé :

8555 Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC), with historically poor outcome. Excellent response of metastatic PSC to immunotherapy was previously reported, but its outcome compared with other NSCLCs is unknown in the immunotherapy era. Methods: NCDB was queried for stage IV NSCLC diagnosed from 2016 to 2020. Patients who were treated with chemotherapy only or immunotherapy only in the first course of treatment were included. Log-rank was used for survival analysis and adjusted by cox regression for age, gender, race, academic/i

Styles APA, Harvard, Vancouver, ISO, etc.

15

Tallman, Jacob E., Fenshen Kuo, Syed M. Alam, et al. "Abstract A029: Transcriptome analysis of variant histology bladder cancer reveals drug target heterogeneity." Clinical Cancer Research 30, no. 10_Supplement (2024): A029. http://dx.doi.org/10.1158/1557-3265.bladder24-a029.

Texte intégral

Résumé :

Abstract Bladder cancers with predominant variant histologic subtypes were excluded from The Cancer Genome Atlas project and other large molecular studies of bladder cancer, limiting our understanding of the molecular biology of tumors with divergent differentiation. We therefore performed an analysis of transcriptomic data from a large cohort of bladder tumors displaying phenotypic plasticity. Tumors were reviewed by a board-certified genitourinary pathologist and the cohort was enriched for tumors displaying divergent differentiation as defined by the WHO classification of tumors. The specim

Styles APA, Harvard, Vancouver, ISO, etc.

16

Pichler, Renate, Eva Compérat, Tobias Klatte, et al. "Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?" Cancers 11, no. 3 (2019): 422. http://dx.doi.org/10.3390/cancers11030422.

Texte intégral

Résumé :

Renal cell carcinoma (RCC) with sarcomatoid differentiation belongs to the most aggressive clinicopathologic phenotypes of RCC. It is characterized by a high propensity for primary metastasis and limited therapeutic options due to its relative resistance to established systemic targeted therapy. Most trials report on a poor median overall survival of 5 to 12 months. Sarcomatoid RCC can show the typical features of epithelial-mesenchymal transition (EMT) and may contain epithelial and mesenchymal features on both the morphological and immunhistochemical level. On the molecular level, next-gener

Styles APA, Harvard, Vancouver, ISO, etc.

17

Guner, Ali, Savaş Karyagar, Ayten Livaoglu, Can Kece, and Uzer Kucuktulu. "Small Bowel Intussusception due to Metastasized Sarcomatoid Carcinoma of the Lung: A Rare Cause of Intestinal Obstruction in Adults." Case Reports in Surgery 2012 (2012): 1–4. http://dx.doi.org/10.1155/2012/962683.

Texte intégral

Résumé :

Although small bowel intussusception is one of the most common abdominal emergencies in childhood, it is rare in adults and usually occurs as a result of an underlying pathology. Sarcomatoid carcinoma, a very rare subtype of lung cancer, rarely metastasizes to small bowel and causes complications. In this paper, we aim to describe a patient with small bowel intussusception caused by an isolated small bowel metastasis of the sarcomatoid carcinoma of the lung by reviewing the literature.

Styles APA, Harvard, Vancouver, ISO, etc.

18

Molina, A. M., S. K. Tickoo, N. Ishill, et al. "Treatment outcome and survival for patients (pts) with sarcomatoid-variant metastatic renal cell carcinoma (RCC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience." Journal of Clinical Oncology 27, no. 15_suppl (2009): e16017-e16017. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e16017.

Texte intégral

Résumé :

e16017 Background: Sarcomatoid-variant represents a spindle cell phenotype of RCC that can be present in any subtype, usually showing aggressive biological behavior. MSKCC experience was studied to provide data on outcome and survival to systemic therapy for metastatic, sarcomatoid-variant RCC. Methods: Clinical features, treatment outcome and survival were reviewed in 63 pts with sarcomatoid-variant metastatic RCC from a database of 650 pts treated at MSKCC with systemic therapy (cytokines, anti-angiogenesis targeted therapy and chemotherapy). Response to therapy, progression-free survival (P

Styles APA, Harvard, Vancouver, ISO, etc.

19

Wang, Feng, Ayse Ece Cali Daylan, Lei Deng, et al. "Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways." Cancers 15, no. 13 (2023): 3372. http://dx.doi.org/10.3390/cancers15133372.

Texte intégral

Résumé :

Immunotherapy has transformed lung cancer management, but PSC remains an aggressive subtype with a poor prognosis. This study investigates the differential expression of PD-L1 and alternative immune checkpoints (ICs; B7x, B7-H3, and HHLA2), and genetic alterations in PSCs. Tumor specimens of 41 PSC patients were evaluated. PD-L1, B7x, B7-H3, and HHLA2 were positive in 75.0%, 67.6%, 73.0%, and 91.9% of tumors, respectively. PD-L1 expression was significantly higher in the epithelial compared to the sarcomatoid component (median TPS: 50% vs. 0%, p = 0.010). Expression of PD-L1 in both components

Styles APA, Harvard, Vancouver, ISO, etc.

20

Miller, Justin W., Jeffrey S. Johnson, Christopher Guske, et al. "Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas." Cancers 17, no. 2 (2025): 326. https://doi.org/10.3390/cancers17020326.

Texte intégral

Résumé :

Renal cell carcinoma (RCC) is a heterogeneous disease that represents the most common type of kidney cancer. The classification of RCC is primarily based on distinct morphological and molecular characteristics, with two broad categories: clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC). Clear cell RCC is the predominant subtype, representing about 70–80% of all RCC cases, while non-clear cell subtypes collectively make up the remaining 20–30%. Non-clear cell RCC encompasses many histopathological variants, each with unique biological and clinical characteristics. Additionally, any RCC su

Styles APA, Harvard, Vancouver, ISO, etc.

21

Rahman, Syed Nahiyaan, Darryl T. Martin, Kandala Keervani, et al. "Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer." Cancers 17, no. 15 (2025): 2536. https://doi.org/10.3390/cancers17152536.

Texte intégral

Résumé :

Background: The importance of lymph node dissection (LND) at the time of radical cystectomy for urothelial carcinoma (UC) is widely accepted despite known risks. The therapeutic benefits of LND for variant subtype bladder cancer (VBC), a heterogenous and distinct set of diseases, are not well established. We aim to characterize the impact of LND on overall survival across VBC subtypes. Methods: The National Cancer Database was queried for all cases of variant subtype bladder cancer managed with radical cystectomy between 2004 and 2020, using the International Classification of Disease-O-3 morp

Styles APA, Harvard, Vancouver, ISO, etc.

22

Al Armashi, Abdul Rahman, Akram Alkrekshi, Anas Al Zubaidi, et al. "Trends and survival of malignant mesothelioma across racial groups between 2000-2019: A real-world study." Journal of Clinical Oncology 41, no. 16_suppl (2023): e20539-e20539. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e20539.

Texte intégral

Résumé :

e20539 Background: Malignant mesothelioma of the pleura (MMP) is a rare and aggressive malignancy and predominantly affects patients of White race in the U.S. Despite treatment advancements, the 5-year survival rate remains between 5% and 10%. Studies assessing racial disparities in MMP are lacking. We conducted a retrospective study to evaluate prevalence, survival and mortality trends among racial groups. Methods: We used the SEER database to determine the racial prevalence of all histological subtypes of MMP between 2000 and 2019. We calculated racial and histological subtype survival Cox p

Styles APA, Harvard, Vancouver, ISO, etc.

23

Jeong, Ji-Seon, Kyung-Ja Cho, Deokhoon Kim, Yoon Se Lee, and Joon Seon Song. "Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma." Pathology - Research and Practice 228 (December 2021): 153678. http://dx.doi.org/10.1016/j.prp.2021.153678.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

Harling, Leanne, Styliani Maria Kolokotroni, Arjun Nair, et al. "Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma." Annals of Thoracic Surgery 107, no. 3 (2019): 929–35. http://dx.doi.org/10.1016/j.athoracsur.2018.09.019.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

25

Mignano, Salvatore E., and Daniel H. Russell. "Nodular Vascular Transformation of the Lymph Node Sinuses Mimicking Sarcomatoid Change in Renal Cell Carcinoma: A Potential Diagnostic Pitfall." International Journal of Surgical Pathology 28, no. 6 (2020): 637–42. http://dx.doi.org/10.1177/1066896920916243.

Texte intégral

Résumé :

Vascular transformation of the lymph node sinuses (VTS) is an uncommon phenomenon that is believed to occur secondary to obstruction of efferent lymphatics, frequently occuring in retroperitoneal lymph nodes draining cancer. The nodular subtype of VTS, in particular, can mimic metastatic cancer, such as metastatic renal cell carcinoma with sarcomatoid differentiation, potentially resulting in inaccurate tumor grading and/or staging. We present a case of nodular VTS mimicking metastatic renal cell carcinoma with sarcomatoid differentiation in a patient with high-grade clear cell renal cell carc

Styles APA, Harvard, Vancouver, ISO, etc.

26

Lofiego, Maria Fortunata, Sara Cannito, Carolina Fazio, et al. "Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy." Epigenomes 5, no. 4 (2021): 27. http://dx.doi.org/10.3390/epigenomes5040027.

Texte intégral

Résumé :

Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a severe prognosis, and with a long-standing need for more effective therapeutic approaches. However, treatment with immune checkpoint inhibitors is becoming an increasingly effective strategy for MPM patients. In this scenario, epigenetic modifications may negatively regulate the interplay between immune and malignant cells within the tumor microenvironment, thus contributing to the highly immunosuppressive contexture of MPM that may limit the efficacy of immunotherapy. Aiming to further improve prospectively the clinical e

Styles APA, Harvard, Vancouver, ISO, etc.

27

Wang, Qian, Yaning Zhang, Meng Ru, et al. "Radical surgery in malignnant pleural mesothelioma (MPM): An analysis of SEER database." Journal of Clinical Oncology 39, no. 15_suppl (2021): 8554. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.8554.

Texte intégral

Résumé :

8554 Background: MPM is an aggressive malignnancy with poor overall prognosis. A combined treatment approach involving radical surgery (RS), radiation (RT) and chemotherapy (CT) provide improved survival compared to systemic treatment alone. Selecting patients who may benefit from RS is challenging. The NCCN guidelines recommend that up to T3N1M0 (Stage IIIA) epithelioid or biphasic MPM should be considered for multimodality therapy incorporating RS. However, the impact of clinical and pathologic features within each histologic subtype of MPM on RS outcomes is unknown. Methods: MPM patients fr

Styles APA, Harvard, Vancouver, ISO, etc.

28

Gębara-Puchniarz, Agnieszka, Beata Hryciuk, Rafał Stec, Cezary Szczylik, Bartłomiej Grala, and Wojciech Kozłowski. "Sarcomatoid renal-cell carcinoma: treatment strategy, review of the literature and a case report." Oncoreview 6, no. 4 (2016): 0. http://dx.doi.org/10.5604/01.3001.0009.5066.

Texte intégral

Résumé :

Introduction: Sarcomatoid renal-cell carcinoma is a very rare cancer characterised with aggressive course of disease and poor prognosis. At present there are no standards of care for this histologic subtype of renal cell carcinoma resistant to various forms of systemic treatment. Methods: The study describes a case of 58 year old woman after left nephrectomy for clear cell carcinoma with sarcomatoid component and after resection of right-kidney tumour for synchronous clear cell carcinoma who received first-line bevacizumab and temsirolimus under the clinical trial, and then second-line chemoth

Styles APA, Harvard, Vancouver, ISO, etc.

29

Devkota, Anirudra, Amrit Paudel, Simit Sapkota, Subash Pandit, and Aashish Baniya. "Case Report: Pulmonary sarcomatoid carcinoma in a female patient from Nepal." F1000Research 10 (August 2, 2021): 723. http://dx.doi.org/10.12688/f1000research.55187.1.

Texte intégral

Résumé :

Sarcomatoid carcinoma of the lung is an uncommon subtype of non-small-cell lung cancer (NSCLC). Even in the early stages, pulmonary sarcomatoid carcinoma (PSC) has a dismal prognosis when compared to other kinds of NSCLC with a mean survival of 9–12 months and a five-year survival rate of around 20%. We present the case of a 68-year-old woman with a two-month history of shortness of breath and cough. Initial computed tomography (CT) scan showed features of interstitial lung disease with chronic obstructive airway changes. After 34 months, the patient’s condition worsened with newer complaints

Styles APA, Harvard, Vancouver, ISO, etc.

30

Millis, Sherri Z., Philip J. Stephens, Jeffrey S. Ross, Vincent A. Miller, Siraj Mahamed Ali, and Jue Wang. "Comprehensive genomic sequencing of prostate sarcomatoid carcinoma tumors identifies differences in genomic alterations compared to prostate adenocarcinoma tumors." Journal of Clinical Oncology 35, no. 6_suppl (2017): 226. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.226.

Texte intégral

Résumé :

226 Background: Sarcomatoid carcinoma of the prostate is a rare variant of prostatic cancer and has a significantly worse prognosis. The genomic features underpinning this rare subtype of malignancy are not well understood, and at present, there are no effective therapies. Methods: Tissue from 1417 prostate cancer patients was assayed by hybrid-capture based comprehensive genomic profiling (CGP) in the course of clinical care to evaluate genomic alterations (GA: base substitutions, indels, amplifications, copy number alterations, fusions/rearrangements) and targeted therapy opportunities. Tumo

Styles APA, Harvard, Vancouver, ISO, etc.

31

Zheng, Yue, Yang Fu, Qin Zhong, Rong Deng, and Yu Zhang. "The treatment of advanced pulmonary sarcomatoid carcinoma." Future Oncology 18, no. 6 (2022): 727–38. http://dx.doi.org/10.2217/fon-2021-1071.

Texte intégral

Résumé :

Pulmonary sarcomatoid carcinoma (PSC) is a pathological subtype of non-small-cell lung cancer. Although the incidence of PSC in lung cancer is very low, it is an aggressive cancer, leading to a poor prognosis. Currently, there is no standard treatment for advanced PSC. Targeted therapy can be used for patients with METex14 mutations and patients with other driver gene mutations may also benefit from treatment. The emergence of immune checkpoint inhibitors also provides potential options for advanced PSC treatment, but more clinical data is needed. Additionally, more research may be warranted t

Styles APA, Harvard, Vancouver, ISO, etc.

32

Gutta, Pranavteja, and Siva Santosh Kumar Gandu. "S3151 Sarcomatoid Hepatocellular Carcinoma: A Dangerous, Spindled Subtype of Hepatocellular Carcinoma." American Journal of Gastroenterology 117, no. 10S (2022): e2023-e2024. http://dx.doi.org/10.14309/01.ajg.0000869244.97170.6a.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

33

Loghin, Andrada, Andrada Raicea, Maria Cătălina Popelea, Ciprian Doru Todea-Moga, Olivér Árpád Vida, and Angela Borda. "Histopathological and immunohistochemical characteristics of adult renal tumors: a five-year retrospective study in Mureş County (Romania)." Romanian Journal of Morphology and Embryology 65, no. 3 (2024): 457–65. http://dx.doi.org/10.47162/rjme.65.3.08.

Texte intégral

Résumé :

Introduction: The incidence of renal tumors increased substantially in the past decades, being responsible for 3% of deaths caused by cancer globally. They constitute a diverse group with varying morphological, immunohistochemical, and molecular characteristics. The severity and prognosis are directly correlated with tumor stage, histopathological aspect, sarcomatoid/rhabdoid features, fat or vascular invasion. Aim: The aim of the study was to assess the prevalence trend, as well as demographic and pathological characteristics of renal tumors in Mureş County Clinical Hospital, Romania, and bor

Styles APA, Harvard, Vancouver, ISO, etc.

34

Giroux Leprieur, Etienne, Martine Antoine, Thibault Vieira, et al. "Clinicopathologic and molecular factors associated with early progressive disease after front-line platinum-doublet chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 30, no. 15_suppl (2012): e18075-e18075. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e18075.

Texte intégral

Résumé :

e18075 Background: The majority of cases of NSCLC are diagnosed at an advanced stage and treated with a platinum-doublet CT. However, some patients are resistant to this treatment and develop early progressive disease. We investigated the clinicopathologic and molecular characteristics of such patients. Methods: All consecutive patients with NSCLC IIIB−IV treated with a platinum-doublet CT between 2003 and 2006 were included. Platinum resistance was defined as early progressive disease at the first tumor assessment according to WHO criteria. The clinical, histologic and molecular characteristi

Styles APA, Harvard, Vancouver, ISO, etc.

35

Paredes Mogica, Jan Alberto, Eduardo Reyes Sanchez, Daniela Arantza Zaragoza Morales, Nathalie Pierre-Louis Guillen, and Manuel Ernesto Magallanes Maciel. "Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed." Case Reports in Oncology 14, no. 3 (2021): 1677–81. http://dx.doi.org/10.1159/000520190.

Texte intégral

Résumé :

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of nonsmall-cell lung cancer (NSCLC). It carries a poor prognosis, even among other subtypes of NSCLC. Currently, most treatment strategies for PSC are derived from regimens aimed at managing soft tissue sarcomas or NSCLC. The use of doxorubicin plus ifosfamide and pemetrexed has been well established in the management of soft tissue carcinoma and other nonsmall-cell lung cancers, respectively. We report the case of a 69-year-old male diagnosed with PSC who was managed with doxorubicin plus ifosfamide and pemetrexed therapy. Our patient i

Styles APA, Harvard, Vancouver, ISO, etc.

36

Nutalapati, Snigdha, Reema Anil Patel, Quan Chen, and Bin Huang. "Epidemiology and survival analysis of non-GIST GI sarcomas: A two-decade analysis of SEER database." Journal of Clinical Oncology 41, no. 4_suppl (2023): 812. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.812.

Texte intégral

Résumé :

812 Background: Primary adult non-GIST (gastrointestinal stromal tumors) gastrointestinal sarcomas are rare, accounting for 1-2% of all GI malignancies. Given the paucity of literature, we aimed to study the epidemiology and clinical outcomes of these sarcomas. Methods: National SEER-18 registry database was analyzed from 2001 to 2019 to identify non-GIST-GI sarcomas among adults aged 20 years and older. Demographics and clinical factors, including age at diagnosis, gender, race, primary cancer site, histology group, tumor grade and treatment, were examined in descriptive analysis. Log-rank te

Styles APA, Harvard, Vancouver, ISO, etc.

37

Sadiq, Abid M., Minael G. Mjemmas, Adnan M. Sadiq, and Gilbert Z. Nkya. "Sarcomatoid hepatocellular carcinoma in a young African female." SAGE Open Medical Case Reports 9 (January 2021): 2050313X2110524. http://dx.doi.org/10.1177/2050313x211052452.

Texte intégral

Résumé :

Sarcomatoid hepatocellular carcinoma is a rare primary malignant liver cancer. The pathogenesis is unclear; however, the risk factors may be similar to that of conventional hepatocellular carcinoma. We present an 18-year-old female who was admitted due to generalized tonic–clonic convulsions. On examination, we palpated a large non-tender mass in the right upper quadrant. An abdominal computed tomography identified it as hepatocellular carcinoma, and spindle-shaped cells were seen on histopathology. She was counseled on her prognosis but opted for local herbal medications rather than chemother

Styles APA, Harvard, Vancouver, ISO, etc.

38

Kwon, Whi-An, Ho Kyung Seo, Geehyun Song, Min-Kyung Lee, and Weon Seo Park. "Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development." Biomedicines 13, no. 1 (2025): 86. https://doi.org/10.3390/biomedicines13010086.

Texte intégral

Résumé :

Urothelial carcinoma (UC) is the most common histological subtype of bladder tumors; however, bladder cancer represents a heterogeneous group of diseases with at least 40 distinct histological subtypes. Among these, the 2022 World Health Organization classification of urinary tract tumors identifies a range of less common subtypes of invasive UC, formerly known as variants, which are considered high-grade tumors, including squamous cell, small-cell, sarcomatoid urothelial, micropapillary, plasmacytoid, and urachal carcinomas, and adenocarcinoma. Their accurate histological diagnosis is critica

Styles APA, Harvard, Vancouver, ISO, etc.

39

Bovolim, Graziele, Walter Henriques da Costa, Gustavo Cardoso Guimaraes, Fernando Augusto Soares, and Isabela Werneck da Cunha. "Mixed papillary-sarcomatoid carcinoma of the penis: report of an aggressive subtype." Virchows Archiv 471, no. 6 (2017): 815–18. http://dx.doi.org/10.1007/s00428-017-2191-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

40

Ishida, Tomo, Yoshinori Kagawa, Atsushi Naito, et al. "Sarcomatoid Carcinoma of the Transverse Colon With Extremely Aggressive Brain Metastases." International Surgery 105, no. 1-3 (2021): 596–602. http://dx.doi.org/10.9738/intsurg-d-20-00023.1.

Texte intégral

Résumé :

Introduction Sarcomatoid carcinoma (SC) is a rare subtype of malignant neoplasm with a poor prognosis that involves both carcinomatous and sarcomatous components. Although it may develop in various organs, SC in the large intestine has rarely been reported. It is not rare for patients with SC to have distant metastasis, reflecting its highly aggressive oncologic features, but cases with brain metastasis on initial visit are rare. In this report, we described a case of SC in the transverse colon with brain metastases whose initial symptom was neurological disorder, and reviewed 31 reported case

Styles APA, Harvard, Vancouver, ISO, etc.

41

Costello, Brian Addis, Ben Zhang, Christine M. Lohse, et al. "Outcomes of patients with sarcomatoid renal cell carcinoma: The Mayo Clinic experience." Journal of Clinical Oncology 31, no. 6_suppl (2013): 359. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.359.

Texte intégral

Résumé :

359 Background: Sarcomatoid renal cell carcinoma (RCC) is an aggressive form of RCC and is associated with a poor prognosis. Standard therapies tend to be less effective in this subset of patients. Methods: Using the Mayo Clinic Nephrectomy Registry, 206 patients with sarcomatoid RCC treated with partial or radical nephrectomy were identified. These patients were characterized based on extent of disease, treatment response and survival. Results: Of these 206, there was no evidence of distant metastases in 110 patients at the time of surgery and the estimated distant metastases-free survival at

Styles APA, Harvard, Vancouver, ISO, etc.

42

Minner, S., J. Schreiner, and W. Saeger. "Adrenal cancer: relevance of different grading systems and subtypes." Clinical and Translational Oncology 23, no. 7 (2021): 1350–57. http://dx.doi.org/10.1007/s12094-020-02524-2.

Texte intégral

Résumé :

Abstract Purpose The subclassification of adrenal cancers according to the WHO classification in ordinary, myxoid, oncocytic, and sarcomatoid as well as pediatric types is well established, but the criteria for each subtype are not sufficiently determined and the relative frequency of the different types of adrenal cancers has not been studied in large cohorts. Therefore, our large collection of surgically removed adrenal cancers should be reviewed o establish the criteria for the subtypes and to find out the frequency of the various types. Methods In our series of 521 adrenal cancers the scor

Styles APA, Harvard, Vancouver, ISO, etc.

43

Keegan, K. A., N. J. Hellenthal, K. Chamie, and T. M. Koppie. "Histopathology in surgically treated renal cell carcinoma: Is there a survival difference when stratified by stage?" Journal of Clinical Oncology 27, no. 15_suppl (2009): 5089. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5089.

Texte intégral

Résumé :

5089 Background: The impact of renal cell carcinoma histopathology (RCC) on survival has been conflicting and limited to retrospective institutional studies. Therefore, we sought to determine the role of RCC histopathology on stage-specific survival rates in a population-based cohort. Methods: We utilized the National Cancer Institute's Surveillance, Epidemiology, and End Results database and identified 21,258 patients who underwent partial or radical nephrectomy for RCC between 1996 and 2004. Patients were stratified based on histopathologic diagnosis (clear cell, papillary, chromophobe, sarc

Styles APA, Harvard, Vancouver, ISO, etc.

44

Saikawa, Hirotaka, Noriyuki Uesugi, Tamotsu Sugai, and Makoto Maemondo. "Pleomorphic carcinoma of the trachea after chemoradiotherapy for laryngeal cancer." BMJ Case Reports 13, no. 10 (2020): e236819. http://dx.doi.org/10.1136/bcr-2020-236819.

Texte intégral

Résumé :

A 66-year-old male patient who had received chemoradiotherapy (CRT) for laryngeal cancer 2 years ago visited a local doctor complaining of dyspnoea and wheezing. CT scan showed narrowing of the trachea caused by a tumour. We intubated the trachea over the tumour using a bronchoscope. A week later, the truncated tracheal tumour obstructed the tracheal tube, compromising the patient’s breathing. We removed the obstructed tube and inserted a new one. We submitted the tissue from the tube to a pathologist. Histopathological diagnosis was pleomorphic carcinoma, a subtype of sarcomatoid carcinoma. T

Styles APA, Harvard, Vancouver, ISO, etc.

45

Takemura, Kosuke, Jeffrey Graham, David Maj, et al. "Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)." Journal of Clinical Oncology 43, no. 5_suppl (2025): 494. https://doi.org/10.1200/jco.2025.43.5_suppl.494.

Texte intégral

Résumé :

494 Background: Immuno-oncology (IO)-based combination therapy with or without anti-vascular endothelial growth factor (VE) has become a standard of care for mnccRCC. However, real-world evidence on the effectiveness of contemporary therapies over traditional targeted therapies against mnccRCC is limited. Methods: Using the IMDC, patients with mnccRCC were classified into five subgroups based on 1L therapies: IOIO, IOVE, CABO, SUN/PAZ, and mammalian target of rapamycin (mTOR). Baseline patient characteristics, clinician assessment of objective response rates (ORRs) as per RECIST 1.1, and overa

Styles APA, Harvard, Vancouver, ISO, etc.

46

Ye, Huihui, Rong Rong Huang, Brian M. Shuch, et al. "CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma." Journal of Clinical Oncology 40, no. 6_suppl (2022): 384. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.384.

Texte intégral

Résumé :

384 Background: Renal cell carcinoma (RCC) comprises a heterogeneous group of tumors of different histological subtypes. Each subtype is characterized by distinct immunohistochemical and molecular features and different biology. Currently, patients with advanced RCC have poor disease outcomes despite recent breakthroughs in immunotherapy. Chimeric antigen receptor (CAR)-T cell therapy has produced remarkably effective and durable clinical responses in hematological malignancies. However, there have been very limited success of CAR-T cell therapy in solid tumors. CD70 and its signaling partner

Styles APA, Harvard, Vancouver, ISO, etc.

47

Menshikov, K. V., A. V. Sultanbaev, Sh I. Musin, et al. "POSSIBILITIES OF THE SECOND LINE OF THERAPY FOR METASTATIC RENAL CELL CARCINOMA. CLINICAL CASE." Oncology bulletin of the Volga region 13, no. 1 (2022): 67–75. http://dx.doi.org/10.32000/2078-1466-2022-1-67-75.

Texte intégral

Résumé :

In 2020, there were about 19,3 million new cancers and 10,0 million cancer deaths worldwide, according to GLOBOCAN. Renal cell carcinoma is one of the ten most commonly diagnosed cancers in the world. Anti-angiogenic drugs targeting VEGF (bevacizumab) and its receptors (sunitinib, sorafenib, pazopanib, and axitinib) are standard therapies. Cabosantinib is an oral small molecule tyrosine kinase inhibitor including MET, VEGF receptors (VEGFR) and AXL. A randomized phase III study METEOR evaluated the efficacy of cabozantinib versus everolimus in patients with renal cell carcinoma that progressed

Styles APA, Harvard, Vancouver, ISO, etc.

48

Ito, Timothy, Jianming Pei, Essel Dulaimi, et al. "Examination of genomic copy number alterations in renal cell carcinoma with sarcomatoid features." Journal of Clinical Oncology 33, no. 7_suppl (2015): 478. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.478.

Texte intégral

Résumé :

478 Background: Sarcomatoid differentiation is an uncommon histological finding in renal cell carcinoma (RCC) that may develop from any RCC subtype and is associated with a very poor prognosis. The identification of genetic alterations that drive this aggressive phenotype could aid in the development of more effective targeted therapies. In this study, we aimed to identify unique copy number alterations (CNAs) in patients with sarcomatoid RCC when compared to those with other RCC subtypes. Methods: Genomic copy number analysis was performed using single nucleotide polymorphism (SNP)-based micr

Styles APA, Harvard, Vancouver, ISO, etc.

49

Reis, Ana Filipa, Thomas A. Odeny, Diana Simão, et al. "A systematic review of immune checkpoint inhibitors (ICI) in non-clear cell renal cell cancer (nccRCC) subtypes." Journal of Clinical Oncology 40, no. 6_suppl (2022): 353. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.353.

Texte intégral

Résumé :

353 Background: ICI were approved for advanced RCC treatment either alone or combined with another ICI or a tyrosine kinase inhibitor. While most trial data derive from clear cell (cc) histology, the differential activity of ICI in nccRCC subtypes is not entirely known. The aim of this analysis is to summarize the reported activity of ICI-based therapies in ncc-subtypes or in tumors with sarcomatoid/rhabdoid features. Methods: A systematic literature search following PRISMA guidelines was performed. PubMed, GoogleScholars and ASCO Database were searched for the key-words “renal cell cancer” an

Styles APA, Harvard, Vancouver, ISO, etc.

50

De Luca-Johnson, J., and M. Zenali. "Gastrointestinal: Sarcomatoid carcinoma of the colon, a rare and highly aggressive tumor subtype." Journal of Gastroenterology and Hepatology 31, no. 1 (2015): 7. http://dx.doi.org/10.1111/jgh.13160.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!